Tối ưu hóa việc sử dụng peginterferon và ribavirin ở các nhóm bệnh nhân khó điều trị

Davis GL, Albright JE, Cook SF, et al.: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331–338. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002, 36:S35–S46. Lok AS, Seeff LB, Morgan TR, et al.: Incidence rates and risk factors associated with hepatocellular carcinoma (HCC) in patients with advanced liver disease due to hepatitis C: results of the HALT-C trial. Presented at the 43rd annual meeting of the European Association for the Study of the Liver (EASL 2008). Milan, Italy; April 23–27, 2008. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346–355. McHutchison JG, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061–1069. Shiffman ML, Ghany MG, Morgan TR, et al.: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103–112. Davis GL, Wong JB, McHutchison JG, et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645–652. Bronowicki JP, Ouzan D, Asselah T, et al.: Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006, 131:1040–1048. Shiffman ML, Salvatore J, Hubbard S, et al.: Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007, 46:371–379. Reddy KR, Shiffman ML, Morgan TR, et al.: Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124–129. Afdhal NH, Dieterich DT, Pockros PJ, et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126:1302–1311. Koirala J, Gandotra SD, Rao S, et al.: Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007, 14:782–787. Schafer A, Wittchen HU, Seufert J, Kraus MR: Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C—a critical review. Int J Methods Psychiatr Res 2007, 16:186–201. Schaefer M, Hinzpeter A, Mohmand A, et al.: Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007, 46:991–998. Raison CL, Broadwell SD, Borisov AS, et al.: Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005, 19:23–27. Raison CL, Woolwine BJ, Demetrashvili MF, et al.: Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007, 25:1163–1174. Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639–644. Patton HM, Patel K, Behling C, et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484–490. Harrison SA: Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006, 43:1168; author reply 1168–1169. Hsu CS, Liu CJ, Liu CH, et al.: High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008, 28:271–277. Muzzi A, Leandro G, Rubbia-Brandt L, et al.: Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005, 42:41–46. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al.: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636–641. D’souza R, Sabin CA, Foster GR: Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005, 100:1509–1515. Hickman IJ, Jonsson JR, Prins JB, et al.: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413–9. Jacobson IM, Brown RS, Jr., Freilich B, et al.: Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007, 46:971–81. Fried MW, Jensen DM, Rodriguez-Torres M, et al.: Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008, 48:1033–43. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265–2271. Conjeevaram HS, Fried MW, Jeffers LJ, et al.: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470–477. Kwo P, Lawitz E, McCone J, et al.: Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 23–27, 2008. Abstract 995. Rodriguez-Torres M, Ankoma-Sey V, Sheikh MY: Rapid and early viral responses to Peginterferon alfa-2a plus ribavirin in treatment-naive Latino vs. non-Latino Caucasians infected with HCV genotype 1; the LATINO Study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 23–27, 2008. Chung RT, Andersen J, Volberding P, et al.: Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451–459. Brown RS Jr, Jacobson IM, Afdhal N: Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial. Presented at Digestive Diseases Week. Los Angeles, CA; May 20–25, 2006. Verma S, Bonacini M, Govindarajan S, et al.: More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006, 101:1817–1823. Hoyumpa A, Sharkey F, Page R, et al.: Greater prevalence of cirrhosis in Hispanics then in Caucasians or African Americans [abstract]. Hepatology 2005, 42(Suppl 1):442. Pol S, Lamorthe B, Thi NT, et al.: Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998, 28:945–950. Perez-Olmeda M, Nunez M, Romero M, et al.: Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. Aids 2003, 17:1023–1028. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839–2848. Shea DO, Tuite H, Farrell G, et al.: Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. J Viral Hepat 2008, 15:482–489. Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol 2008, 48:353–367. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al.: Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007, 38:32–38. Rockstroh JK, Bhagani S, Benhamou Y, et al.: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82–88. Alvarez D, Dieterich DT, Brau N, et al.: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006, 13:683–689. Sulkowski MS, Thomas DL, Mehta SH, et al.: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182–189. Yu JW, Wang GQ, Sun LJ, et al.: Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007, 22:832–836. Jensen DM, Morgan TR, Marcellin P, et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954–960. Marcellin P, Hadziyannis SJ, Berg T: Virological response at 4 weeks and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40kd) plus ribavirin. Presented at the 42nd Annual Meeting for the European Association of the Liver. Barcelona, Spain; April 11–15, 2007. Berg T, von Wagner M, Nasser S, et al.: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086–1097. Pearlman BL, Ehleben C, Saifee S: Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007, 46:1688–1694. Sanchez-Tapias JM, Diago M, Escartin P, et al.: Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006, 131:451–460. Jensen D, Freilich B, Andreone P, et al.: Pegylated interferon alfa-2a (40kd) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kd)/RBV: final efficacy and safety outcomes of the REPEAT study. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007. Poynard T SE, Terg R: Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponsers (NR): final results of the EPIC3 program. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 23–27, 2008. Cheruvattath R, Rosati MJ, Gautam M, et al.: Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci 2007, 52:732–736. McHutchison JG, Shiffman ML, Terrault N, et al.: A phase 2b study of telaprevir with peginterferon-alpha-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alpha-2a/b and ribavirin therapy: PROVE3 interim results. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; October 31–November 4, 2008. Bacon B, Regev A, Ghalib RH, et al.: The DIRECT trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment of nonresponders to previous pegylated interferon plus ribavirin: sustained virologic response data. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007. Berg C, Goncales FL Jr, Bernstein DE, et al.: Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006, 13:435–440. Everson GT, Hoefs JC, Seeff LB, et al.: Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006, 44:1675–1684. Crippin JS, McCashland T, Terrault N, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8:350–355. Marotta P CC, Wong D: Impact of advanced fibrosis and cirrhosis on sustained virologic response of HCV G1- infected patients: results of the Canadian POWeR program. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; October 31–November 4, 2008. Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255–262. Forns X, Garcia-Retortillo M, Serrano T, et al.: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003, 39:389–396. Berenguer M: Outcome of posttransplantation hepatitis C virus disease—is it the host, the virus, or how we modify the host and/or the virus? Liver Transpl 2002, 8:889–891. Berenguer M: Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008, 49:274–287. Chalasani N, Manzarbeitia C, Ferenci P, et al.: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289–298. Saab S, Oh MK, Ibrahim AB, et al.: Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007, 13:1032–1038. Hanouneh IA, Miller C, Aucejo F, et al.: Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008, 14:53–58. Fabrizi F, Bunnapradist S, Lunghi G, et al.: Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence. Minerva Urol Nefrol 2004, 56:249–257. Finelli L, Miller JT, Tokars JI, et al.: National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005, 18:52–61. Fabrizi F, Dixit V, Messa P, Martin P: Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008, 15:79–88. Carriero D, Fabrizi F, Uriel AJ, et al.: Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008, 31:295–302. Berenguer M: Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008, 48:1690–1699.